Trial Profile
A Retrospective cohort study on treatment patterns and adherence with Deferasirox iron chelation therapy in patients with Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload; Myelodysplastic syndromes
- Focus Therapeutic Use
- 17 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology